

## Efficient Chiral Induction by Diene Iron-Tricarbonyl Moiety. IV.<sup>1)</sup>: Asymmetric Total Synthesis of a Piperidine Alkaloid, SS20846A

Yoshiji TAKEMOTO, Shigeo UEDA, Jun TAKEUCHI, Yasutaka BABA, and Chuzo IWATA\*

Faculty of Pharmaceutical Sciences, Osaka University, 1-6 Yamada-oka, Suita, Osaka 565, Japan.

Received June 2, 1997; accepted August 8, 1997

By  $\text{LiClO}_4$ -catalyzed cycloaddition with Danishefsky's diene **5**, an optically active 1-azatriene  $\text{Fe}(\text{CO})_3$  complex was converted into the 2-substituted dehydropiperidinone **8**, from which a piperidine alkaloid **1** (SS20846A) was synthesized in an enantiomerically pure form *via* successive reduction and removal of the protecting groups. Although the reduction of the ketone **3** proceeded with *cis*-selectivity even with a hindered reducing agent, the desired *trans*-alcohol **4** could be obtained by the reaction with sodium borohydride in the presence of cerium(III) chloride. The *cis*-selective reduction of **3** originates from the equatorial attack of a hydride on conformer A, in which the diene  $\text{Fe}(\text{CO})_3$  moiety is axially oriented due to the severe steric hindrance with the *p*-methoxyphenyl (PMP) group on the nitrogen atom. However, the cerium salt reverses the stereoselectivity of the hydride reduction of **3**.

**Key words** piperidine alkaloid; iron-tricarbonyl complex; [4+2] type cycloaddition; SS20846A; hydride reduction; cerium(III) chloride

Heterocyclic compounds containing the piperidine ring system have attracted much interest by virtue of their varied and clinically useful biological actions. SS20846A (**1**) was first isolated from *Streptomyces* sp. S20846 in 1986 as a piperidine alkaloid which possesses a restrictive action upon the digestive system.<sup>2)</sup> Later, **1** was proposed to be a biosynthetic intermediate of streptazolin, which has strong antimicrobial activity<sup>3)</sup> (Fig. 1). Though **1** appears to be a novel lead compound for agents with anti-convulsant activity, it has not been synthesized, and its absolute stereochemistry is still unknown. We, therefore, decided to synthesize **1** starting from a chiral dienal  $\text{Fe}(\text{CO})_3$  complex **2**<sup>4)</sup> with the aim of determining the absolute stereochemistry. Our retrosynthetic analysis is shown in Chart 1. The 4-piperidinone skeleton could be constructed by a [4+2] type cycloaddition of a 1-azatriene  $\text{Fe}(\text{CO})_3$  complex derived from **2** with 1-methoxy-3-(trimethylsilyloxy)-1,3-butadiene (Danishefsky's diene) **5**. The cycloaddition had been developed in our laboratory and demonstrated to proceed with high stereoselectivity and a predictable stereochemical course.<sup>5a,b)</sup> The successive reductions of the 4-piperidinone would provide the 4 $\alpha$ -alcohol **4**, from which the two protecting groups can be removed by oxidative treatment to give the desired product **1**. After examination of the synthetic route, we found that the hydride reduction of **3** tends to afford the 4 $\beta$ -alcohol **9**, but not the desired product **4**. However, the reaction with sodium borohydride in the presence of cerium(III) chloride gave **4** as a major product. We have already described the first asymmetric synthesis of **1** in a previous communication.<sup>5b)</sup> The report details the asymmetric synthesis of **1** and determination of its absolute stereochemistry, along with some results concern-

ing the reduction of **3** to the *trans*-alcohol **4**.

### Results and Discussion

Although the chiral non-racemic dienal complex (2*R*)-**2** has been prepared by several groups,<sup>4)</sup> these methods are not convenient for a large-scale preparation. Therefore, we first started to develop a more efficient route to (2*R*)-**2**. For this purpose, we chose a known compound **6**<sup>6)</sup> as a chiral starting material. Hydrolysis of the ester **6** with a 4M KOH solution in refluxing ethanol gave the corresponding carboxylic acid **7**,<sup>7)</sup> which was converted into **2** by sequential chlorination and reduction with  $(\text{PPh}_3)_2\text{-CuBH}_4$ .<sup>8)</sup> From our previous report,<sup>5)</sup> it was clear that a PMP (*p*-methoxyphenyl)imine was the best choice for the next cyclization in terms of diastereoselectivity and ease of removal. Then, **2** was condensed with *p*-anisidine and reaction of the corresponding imine complex with **5** in methylene chloride in the presence of an equivalent amount of  $\text{LiClO}_4$  at room temperature gave the dehydropiperidinone (6*S*,1'*R*)-**8** in 84% yield with high diastereoselectivity.

Having the requisite cycloadduct **8** in hand, we next examined the transformation of **8** into the natural product




Fig. 1




Chart 1

\* To whom correspondence should be addressed.





Chart 2

Table 1. Reduction of the 4-Piperidinone **3** with Several Reducing Agents

Entry	Reaction conditions	Yield (%)	Ratio (4/9)
1	L-Selectride, THF, $-78^{\circ}\text{C}$	92	11/89 <sup>a)</sup>
2	DIBAL-H, $\text{CH}_2\text{Cl}_2$ , $-78^{\circ}\text{C}$	81	39/61 <sup>b)</sup>
3	$\text{NaBH}_4$ , MeOH, $0^{\circ}\text{C}$	83	29/71 <sup>b)</sup>
4	$\text{NaBH}_4$ , $\text{CeCl}_3 \cdot 7\text{H}_2\text{O}$ , MeOH, $-78^{\circ}\text{C}$	77	70/30 <sup>a)</sup>

<sup>a)</sup> These values were calculated from the isolated yields. <sup>b)</sup> These values were determined by measuring  $^1\text{H-NMR}$  spectra of the mixture of **4** and **9**.

**1.** Although the conjugate reduction of **8** with L-Selectride proceeded smoothly to give rise to the saturated ketone **3** in 80% yield, the following 1,2-hydride reduction of **3** was troublesome. In the expectation of predominant production of the 2,4-*trans*-adduct **4**, generated from the equatorial attack of a hydride on a chair-like conformer,<sup>9a,b)</sup> **3** was treated with L-Selectride at  $-78^{\circ}\text{C}$ . However, the 2,4-*cis*-adduct **9** was obtained in 82% yield as a major product along with a 10% yield of **4** (Table 1, entry 1). From a nuclear Overhauser effect (NOE) experiment on the ketone **3**, it was found that the diene  $\text{Fe}(\text{CO})_3$  moiety of **3** is axially located in the preferred conformer A to avoid severe interaction with the protecting group (PMP) on the nitrogen (Fig. 2). Therefore, the hydride would attack the ketone of **3** predominantly from the  $\beta$ -site of conformer A due to the 1,3-diaxial interaction with the diene  $\text{Fe}(\text{CO})_3$  complex on C2 to give the *cis*-adduct **9**. Table 1 shows that **9** was always a major product, irrespective of the reducing reagent employed. Even using less hindered reagents such as diisobutylaluminum hydride (DIBAL-H) and sodium borohydride (entries 2, 3), there were only marginal increases in the yield of **4** and we could not reverse the ratio of **4/9**. After many experiments, we finally found that reduction of **3** with sodium borohydride in methanol in the presence of cerium(III) chloride<sup>9c)</sup> afforded the desired *trans*-adduct **4** as a major product (total 77% yield, **4/9** = 70/30) (entry 4). Though the role of  $\text{CeCl}_3$  in reversing the ratio of **4/9** is not clear, it is assumed that the coordination of cerium salts to the ketone and/or amine groups at the less hindered site, that is

Fig. 2. Plausible Mechanism of the Reduction of **3** to **4** and **9** and the Results of NOE Experiments

the upper side, obliges the hydride to change its reaction trajectory from downward to upward (Fig. 2 B).

The relative stereochemistries of **4** and **9** were determined from NOE experiments (500 MHz  $^1\text{H-NMR}$ ). The observation of NOE enhancement between C4-H and C1'-H in **4** indicates that the hydroxyl group at C4 is located *trans* to the diene  $\text{Fe}(\text{CO})_3$  group at C2, that is, **4** is a (2*S*,4*S*,1'*R*)-adduct (Fig. 2 D). On the other hand, the observation of NOE enhancement between C4-H and C2-H in **9** indicates that the hydroxyl group at C4 is located *cis* to the diene  $\text{Fe}(\text{CO})_3$  group at C2, that is **9** is a (2*S*,4*R*,1'*R*)-adduct (Fig. 2 C).

Finally, simultaneous removal of the protecting groups [PMP,  $\text{Fe}(\text{CO})_3$ ] was accomplished by treatment of the *trans*-adduct **4** with ceric(IV) ammonium nitrate (CAN)<sup>10)</sup> in acetonitrile to give a synthetic natural product (SS20846A) in a chiral form (2*S*,4*S*). Judging from the spectral data, the synthetic sample is identical to the natural product.<sup>1,2)</sup> Furthermore, the specific rotation of **1**,  $[\alpha]_{\text{D}}^{24} -15.2^{\circ}$  ( $c=0.53$ ,  $\text{CHCl}_3$ ) [lit.  $[\alpha]_{\text{D}}^{20} -15^{\circ}$  ( $c=1.00$ ,  $\text{CHCl}_3$ )<sup>2b)</sup>], confirms that our synthetic sample has the same absolute configuration as the natural product.

These results indicate that the natural SS20846A has (2*S*,4*S*)-configuration.

We have succeeded in the first asymmetric synthesis of SS20846A in an enantiomerically pure form by using 1) a highly stereoselective [4+2] type cycloaddition of the PMP-imine Fe(CO)<sub>3</sub> complex with Danishefsky's diene **5** in the presence of LiClO<sub>4</sub> and 2) a CeCl<sub>3</sub>-mediated hydride reduction of the *N*-substituted 4-piperidinone **3** to the desired 2,4-*trans*-alcohol **4**.

### Experimental

All melting points were determined with a Yanagimoto MP-21 melting point apparatus and are uncorrected. Optical rotations were measured using a JASCO DIP-360 digital polarimeter. IR spectra were measured with a Horiba FT-210 IR spectrometer using a neat sample on KBr powder by the diffuse reflection measurement method. <sup>1</sup>H-NMR spectra were measured with a JEOL JNM-GX500 spectrometer (500 MHz). <sup>13</sup>C-NMR spectra were measured with a Varian VXR-200 spectrometer (50 MHz). All signals are expressed as ppm downfield from tetramethylsilane used as an internal standard ( $\delta$  value). The following abbreviations are used: singlet (s), doublet (d), triplet (t), multiplet (m), broad (br). Mass spectra were taken with a Shimadzu QP-1000 mass spectrometer. High-resolution mass spectra (HR-MS) were measured with a JEOL JMS-D300 spectrometer. Unless otherwise noted, all reactions were performed in anhydrous solvents. Merck Kieselgel 60 was used as an adsorbent for column chromatography. All extracts were dried over anhydrous MgSO<sub>4</sub>.

**(2*R*,5*S*)-Tricarbonyl[2-5- $\eta$ -(2*E*,4*E*)-2,4-hexadienyl]iron (2)** A 4 M aqueous solution of potassium hydroxide (3 ml) was added to a solution of **6** (430 mg, 1.22 mmol), prepared according to the reported procedure,<sup>6)</sup> in ethanol (12 ml), and the mixture was refluxed for 2 h. After acidification with 10% HCl solution at 0 °C, the mixture was extracted with dichloromethane three times and the combined extracts were dried and concentrated *in vacuo*. The residue was purified by SiO<sub>2</sub> column chromatography with CHCl<sub>3</sub>/MeOH = 15/1 to give the carboxylic acid **7** (273 mg, 89%). Oxalyl chloride (167  $\mu$ l, 1.90 mmol) was added to a solution of **7** (239 mg, 0.948 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (4 ml) at 0 °C under a nitrogen atmosphere. After having been stirred at room temperature for 2 h, the mixture was concentrated *in vacuo* to give an oily residue. A solution of the crude residue in acetone (3 ml) was added to a mixture of (PPh<sub>3</sub>)<sub>2</sub>CuBH<sub>4</sub> (865 mg, 1.42 mmol), PPh<sub>3</sub> (7.45 mg, 2.84 mmol), and acetone (10 ml) at room temperature and the whole was stirred for 1 h. It was filtered through a pad of Celite, and the filtrate was concentrated *in vacuo*. The residue was purified by SiO<sub>2</sub> column chromatography with AcOEt/hexane = 1/10 to give the aldehyde **2** (182 mg, 81%) as a yellow oil.  $[\alpha]_D^{22}$   $-112^\circ$  ( $c=0.770$ , CHCl<sub>3</sub>); lit.  $[\alpha]_D$   $-112^\circ$  ( $c=1.0$ , CHCl<sub>3</sub>). <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ : 1.26 (dd, 1H,  $J=4.3$ , 8.5 Hz, C2-H), 1.51 (d, 3H,  $J=6.1$  Hz, C6-Me), 1.70 (qd, 1H,  $J=6.1$ , 8.5 Hz, C5-H), 5.29 (dd, 1H,  $J=4.9$ , 8.5 Hz, C4-H), 5.76 (dd, 1H,  $J=4.9$ , 8.5 Hz, C3-H), 9.26 (d, 1H,  $J=4.3$  Hz, C1-H). IR (KBr): 2069 (CO), 1992 (CO), 1979 (CO), 1676 (C=O), 1657 (C=O) cm<sup>-1</sup>. MS  $m/z$  (%): 236 (M<sup>+</sup>, 43), 180 (49), 179 (29), 152 (100), 151 (56), 148 (46).

**(6*S*,1'*R*,4'*S*)-Tricarbonyl[1'-4'- $\eta$ -(1'*E*,3'*E*)-2,3-didehydro-1-*p*-methoxyphenyl-6-(1',3'-pentadienyl)piperidin-4-one]iron (8)** A mixture of **2** (892 mg, 3.78 mmol), *p*-anisidine (466 mg, 3.78 mmol), 3A molecular sieves (MS 3A) (900 mg), and dry benzene (20 ml) was stirred at room temperature for 2 h. Concentration of the reaction mixture *in vacuo* gave the desired product (361 mg). <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ : 1.49 (d, 3H,  $J=6.0$  Hz, C5-Me), 1.59 (m, 1H, C5-H), 1.79 (dd, 1H,  $J=7.6$ , 8.4 Hz, C2-H), 3.80 (s, 3H, OMe), 5.23 (dd, 1H,  $J=4.9$ , 9.0 Hz, C4-H), 5.69 (dd, 1H,  $J=4.9$ , 8.4 Hz, C3-H), 6.86 (d, 2H,  $J=9.0$  Hz, Ar-H), 7.03 (d, 2H,  $J=9.0$  Hz, Ar-H), 7.62 (d, 1H,  $J=7.6$  Hz, ArN=C<sub>H</sub>). IR (KBr): 2029 (CO), 1952 (CO), 1618, 1508, 1273, 1244, 1038 cm<sup>-1</sup>. MS  $m/z$  (%): 341 (M<sup>+</sup>, 1.0), 313 (52), 200 (100). Lithium perchlorate (403 mg, 3.79 mmol) was added to a solution of the imine (1.29 g, 3.78 mmol) and **5** (1.30 g, 7.57 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 ml) at room temperature and the resulting suspension was stirred at room temperature for 8 h. The reaction was quenched with aqueous NaHCO<sub>3</sub> solution, and the mixture was extracted with CH<sub>2</sub>Cl<sub>2</sub>. The extract was washed with water and brine, dried, and then concentrated *in vacuo*. The residue was chromatographed (hexane/AcOEt = 1/1) to give **8** as a sole product (1.30 g, 84%). A yellow oil.  $[\alpha]_D^{21}$  + 16.2° ( $c=2.75$ , CHCl<sub>3</sub>). <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ : 1.09 (qd, 1H,

$J=6.8$ , 8.6 Hz, C4'-H), 1.24 (dd, 1H,  $J=6.8$ , 7.7 Hz, C1'-H), 1.36 (d, 3H,  $J=6.8$  Hz, C4'-Me), 2.58 (br, 1H,  $J=16.2$  Hz, C5-Ha), 3.08 (dd, 1H,  $J=6.0$ , 16.2 Hz, C5-Hb), 3.84 (s, 3H, OMe), 4.08 (br dd, 1H,  $J=6.0$ , 6.8 Hz, C6-H), 5.07 (m, 2H, C2'-H, C3'-H), 5.12 (d, 1H,  $J=7.7$  Hz, C3-H), 6.95 (m, 2H, Ar-H), 7.17 (m, 2H, Ar-H), 7.30 (dd, 1H,  $J=1.7$ , 7.7 Hz, C2-H). <sup>13</sup>C-NMR (CDCl<sub>3</sub>)  $\delta$ : 18.8 (C4'-Me), 42.5 (C5), 55.5 (OMe), 56.9 (C4'), 58.8 (C1'), 61.4 (C6), 80.5 (C2'), 85.8 (C3'), 100.1 (C3), 114.8 (C2), 123.0 (ArC), 137.2 (ArC), 148.8 (ArC), 157.4 (ArC), 190.2 (C4), 211.5 (CO). IR (KBr): 2040 (CO), 1965 (CO), 1643 (C=O), 1579, 1510, 1247, 1036 cm<sup>-1</sup>. MS  $m/z$  (%): 409 (M<sup>+</sup>, 0.1), 382 (1.8), 354 (19.1), 326 (100). *Anal.* Calcd for C<sub>20</sub>H<sub>19</sub>FeNO<sub>5</sub>: C, 58.70; H, 4.68; N, 3.42. Found: C, 58.78; H, 4.77; N, 3.34.

**(2*S*,1'*R*,4'*S*)-Tricarbonyl[1'-4'- $\eta$ -(1'*E*,3'*E*)-1-*p*-methoxyphenyl-2-(1',3'-pentadienyl)piperidin-4-one]iron (3)** A 1 M solution of L-Selectride in tetrahydrofuran (THF) (1.47 ml) was added to a stirred solution of **8** (400 mg, 0.978 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 ml) at  $-78^\circ\text{C}$  under a nitrogen atmosphere and the whole was stirred for 1 h. The mixture was quenched with a saturated NaHCO<sub>3</sub> solution and extracted with CH<sub>2</sub>Cl<sub>2</sub> three times. The combined extracts were washed with water and brine, dried, and then concentrated *in vacuo*. The residue was purified by SiO<sub>2</sub> column chromatography with hexane/AcOEt = 3/1 to give **3** (322 mg, 80%) as a yellow oil:  $[\alpha]_D^{20}$   $-48.9^\circ$  ( $c=0.741$ , CHCl<sub>3</sub>). <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ : 0.90 (dd, 1H,  $J=7.7$ , 8.6 Hz, C1'-H), 1.11 (qd, 1H,  $J=6.0$ , 8.6 Hz, C4'-H), 1.37 (d, 3H,  $J=6.0$  Hz, C4'-Me), 2.33 (dd, 1H,  $J=3.4$ , 14.5 Hz, C5-H<sub>eq</sub>), 2.47 (br d, 1H,  $J=13.7$  Hz, C3-H<sub>eq</sub>), 2.58 (ddd, 1H,  $J=6.8$ , 12.0, 14.5 Hz, C5-H<sub>ax</sub>), 2.80 (dd, 1H,  $J=6.0$ , 13.7 Hz, C3-H<sub>ax</sub>), 3.51 (ddd, 1H,  $J=3.4$ , 12.0, 13.7 Hz, C6-H<sub>ax</sub>), 3.7–3.9 (m, 1H, C6-H<sub>eq</sub>), 3.78 (s, 3H, OMe), 4.01 (dd, 1H,  $J=6.0$ , 7.7 Hz, C2-H), 5.01 (dd, 1H,  $J=5.1$ , 8.6 Hz, C3'-H), 5.10 (dd, 1H,  $J=5.1$ , 8.6 Hz, C2'-H), 6.86 (d, 2H,  $J=9.2$  Hz, Ar-3'H), 6.94 (d, 2H,  $J=9.2$  Hz, Ar-2'H). <sup>13</sup>C-NMR (CDCl<sub>3</sub>)  $\delta$ : 18.8 (C5'), 39.9 (C5), 43.7 (C6), 46.0 (C3), 55.4 (OMe), 58.1 (C4'), 60.6 (C1'), 61.5 (C2), 81.6 (C2'), 85.4 (C3'), 114.6 (ArC), 117.8 (ArC), 142.0 (ArC), 153.5 (ArC), 208.1 (C4), 211.6 (CO). IR (KBr): 2040 (CO), 1971 (CO), 1713 (C=O), 1512, 1261, 1248, 1036 cm<sup>-1</sup>. MS  $m/z$  (%): 411 (M<sup>+</sup>, 3.1), 328 (21), 327 (100). *Anal.* Calcd for C<sub>20</sub>H<sub>21</sub>FeNO<sub>5</sub>: C, 58.41; H, 5.15; N, 3.41. Found: C, 58.30; H, 5.16; N, 3.35.

**(2*S*,4*S*,1'*R*,4'*S*)-Tricarbonyl[1'-4'- $\eta$ -(1'*E*,3'*E*)-1-*p*-methoxyphenyl-2-(1',3'-pentadienyl)piperidin-4-ol]iron (4) and (2*S*,4*R*,1'*R*,4'*S*)-Tricarbonyl[1'-4'- $\eta$ -(1'*E*,3'*E*)-1-*p*-methoxyphenyl-2-(1',3'-pentadienyl)piperidin-4-ol]iron (9)** (Table 1, Entry 1): A 1 M solution of L-Selectride in THF (1.47 ml) was added to a stirred solution of **3** (32.0 mg, 0.0778 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 ml) at  $-78^\circ\text{C}$  under a nitrogen atmosphere and the whole was stirred for 1 h. The mixture was quenched with a saturated NaHCO<sub>3</sub> solution at 0 °C, and extracted with CH<sub>2</sub>Cl<sub>2</sub> three times. The combined extracts were washed with water and brine, dried, and then concentrated *in vacuo*. The residue was purified by SiO<sub>2</sub> column chromatography with hexane/AcOEt = 3/1 to give **4** (3.2 mg, 10%) and **9** (26.3 mg, 82%).

(Entry 2): A 1.0 M solution of DIBAL-H in toluene (41  $\mu$ l) was added to a stirred solution of **3** (8.4 mg, 0.0204 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 ml) at  $-78^\circ\text{C}$  under a nitrogen atmosphere and the whole was stirred for 1 h. After having been quenched with a saturated NH<sub>4</sub>Cl solution, the mixture was filtered through a pad of Celite and washed with CH<sub>2</sub>Cl<sub>2</sub>. The combined extracts were washed with water and brine, dried, and then concentrated *in vacuo*. The residue was purified by SiO<sub>2</sub> column chromatography with hexane/AcOEt = 1/1 to give a mixture of **4** and **9** (6.8 mg, 81%). The ratio of **4/9** was determined from the 500 MHz NMR spectrum.

(Entry 3): A stirred solution of **3** (7.7 mg, 0.0187 mmol) in methanol (1 ml) was treated with NaBH<sub>4</sub> at 0 °C, and the whole was stirred for 30 min. The mixture was quenched with water, and extracted with AcOEt. The extract was washed with water and brine, dried, and then concentrated *in vacuo*. The residue was purified by SiO<sub>2</sub> column chromatography with hexane/AcOEt = 1/1 to give a mixture of **4** and **9** (6.4 mg, 83%). The ratio of **4/9** was determined from the 500 MHz NMR spectrum.

(Entry 4): A mixture of the ketone **3** (167 mg, 0.406 mmol), CeCl<sub>3</sub>·7H<sub>2</sub>O (454 mg, 1.22 mmol), and methanol (4 ml) was treated with NaBH<sub>4</sub> (15.3 mg, 0.406 mmol) at  $-78^\circ\text{C}$ . The whole was quenched with water at 0 °C and extracted with CH<sub>2</sub>Cl<sub>2</sub> three times. The combined extracts were washed with water and brine, dried, and then concentrated *in vacuo*. The residue was purified by SiO<sub>2</sub> column chromatography with hexane/AcOEt = 5/1 to give **4** (90.4 mg, 54%) and **9** (38.8 mg, 23%). **4**: A yellow oil.  $[\alpha]_D^{21}$  + 24.8° ( $c=0.802$ , CHCl<sub>3</sub>). <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ : 0.97

(qd, 1H,  $J=6.3$ , 8.5 Hz, C4'-H), 1.04 (dd, 1H,  $J=6.0$ , 9.4 Hz, C1'-H), 1.34 (d, 3H,  $J=6.3$  Hz, C4'-Me), 1.55 (dddd, 1H,  $J=4.3$ , 10.3, 11.1, 11.1 Hz, C5-H<sub>ax</sub>), 1.5—1.7 (br s, 1H), 1.79 (ddd, 1H,  $J=5.1$ , 12.8, 12.8 Hz, C3-H<sub>ax</sub>), 1.94 (br d, 1H,  $J=10.3$  Hz, C5-H<sub>eq</sub>), 2.09 (br d, 1H,  $J=12.8$  Hz, C3-H<sub>eq</sub>), 3.08 (ddd, 1H,  $J=2.6$ , 11.1, 12.8 Hz, C6-H<sub>ax</sub>), 3.38 (br d, 1H,  $J=12.8$  Hz, C6-H<sub>eq</sub>), 3.78 (s, 3H, OMe), 3.87 (br dd, 1H,  $J=5.1$ , 6.0 Hz, C2-H), 4.00 (m, 1H, C4-H), 4.99 (dd, 1H,  $J=5.1$ , 8.5 Hz, C3'-H), 5.12 (dd, 1H,  $J=5.1$ , 9.4 Hz, C2'-H), 6.85 (m, 4H, Ar-H). <sup>13</sup>C-NMR (CDCl<sub>3</sub>)  $\delta$ : 18.8 (C4'-Me), 33.9 (C5), 38.7 (C3), 42.6 (C6), 55.4 (OMe), 57.3 (C4'), 59.0 (C2), 60.6 (C1'), 64.8 (C4), 81.3 (C2'), 84.3 (C3'), 114.4 (ArC), 118.6 (ArC), 143.4 (ArC), 153.1 (ArC), 211.8 (CO). IR (KBr): 3300 (OH), 2945, 2038 (CO), 1975 (CO), 1510, 1246, 1039 cm<sup>-1</sup>. MS  $m/z$  (%): 413 (M<sup>+</sup>, 5.6), 329 (100), 273 (10), 235 (24). HR-MS Calcd for C<sub>20</sub>H<sub>23</sub>FeNO<sub>5</sub>: 413.0923. Found: 413.0912. **9**: A yellow oil.  $[\alpha]_D^{22} +8.05^\circ$  ( $c=1.10$ , CHCl<sub>3</sub>). <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ : 0.89 (qd, 1H,  $J=5.5$ , 8.6 Hz, C4'-H), 1.15 (dd, 1H,  $J=5.1$ , 8.6 Hz, C1'-H), 1.29 (d, 3H,  $J=5.5$  Hz, C4'-Me), 1.5—1.7 (m, 3H, C3-H<sub>ax</sub>, C5-H<sub>ax</sub>, OH), 1.88 (m, 1H, C5-H<sub>eq</sub>), 2.19 (br d, 1H,  $J=12.2$  Hz, C3-H<sub>eq</sub>), 2.85 (br dd, 1H,  $J=12.2$  Hz, C6-H<sub>ax</sub>), 3.20 (m, 2H, C2-H, C6-H<sub>eq</sub>), 3.80 (s, 3H, OMe), 3.86 (m, 1H, C4-H), 4.94 (dd, 1H,  $J=4.9$ , 8.6 Hz, C3'-H), 5.09 (dd, 1H,  $J=4.9$ , 8.6 Hz, C2'-H), 6.87 (d, 2H,  $J=8.5$  Hz, Ar-H), 7.03 (d, 2H,  $J=8.5$  Hz, Ar-H). <sup>13</sup>C-NMR (CDCl<sub>3</sub>)  $\delta$ : 18.8 (C4'-Me), 33.9 (C5), 40.7 (C3), 51.2 (C6), 55.4 (OMe), 57.5 (C4'), 59.1 (C2), 64.5 (C1'), 67.8 (C4), 80.5 (C2'), 84.3 (C3'), 114.5 (ArC), 124.0 (ArC), 144.1 (ArC), 155.8 (ArC), 212.1 (CO). IR (KBr): 3394 (OH), 2931, 2038 (CO), 1969 (CO), 1510, 1443, 1246, 1039 cm<sup>-1</sup>. MS  $m/z$  (%): 413 (M<sup>+</sup>, 8.8), 357 (16), 329 (100), 273 (31), 255 (17), 235 (41). HR-MS Calcd for C<sub>20</sub>H<sub>23</sub>FeNO<sub>5</sub>: 413.0922. Found: 413.0914.

**(2S,4S)-(1'E,3'E)-1',3'-pentadienylpiperidin-4-ol (SS20846A)** CAN (3.98 g, 7.26 mmol) was added slowly to a solution of **4** (300 mg, 0.726 mmol) in CH<sub>3</sub>CN (7 ml) at -30 °C. The mixture was stirred for 30 min, quenched with a 2 N NaOH solution and extracted with AcOEt three times. The combined extracts were washed with brine, dried, and then concentrated *in vacuo*. The residue was purified by SiO<sub>2</sub> column chromatography with MeOH/CH<sub>2</sub>Cl<sub>2</sub>/28% NH<sub>4</sub>OH = 15/90/2 to give **1** (77.7 mg, 64%) as a brownish oil.  $[\alpha]_D^{24} -15.2^\circ$  ( $c=0.53$ , CHCl<sub>3</sub>). <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ : 1.57 (ddd, 1H,  $J=2.6$ , 11.1, 13.7 Hz, C3-H<sub>ax</sub>), 1.63 (br d, 1H,  $J=14.5$  Hz, C5-H), 1.65—1.80 (m, 2H, C3-H<sub>eq</sub>, C5-H), 1.73 (d, 3H,  $J=6.8$  Hz, C4'-Me), 1.9—2.2 (br s, 2H, OH, NH), 2.88 (br d, 1H,  $J=12.0$  Hz, C6-H<sub>eq</sub>), 3.09 (ddd, 1H,  $J=2.6$ , 12.0, 12.0 Hz, C6-H<sub>ax</sub>), 3.57 (br dd, 1H,  $J=6.8$ , 11.1 Hz, C2-H), 4.16 (br dd, 1H,  $J=2.6$ , 3.4 Hz, C4-H), 5.52 (dd, 1H,  $J=6.8$ , 15.4 Hz, C1'-H), 5.66 (qd, 1H,  $J=6.8$ ,

14.5 Hz, C4'-H), 6.02 (dd, 1H,  $J=10.3$ , 15.4 Hz, C2'-H), 6.15 (dd, 1H,  $J=10.3$ , 14.5 Hz, C3'-H). <sup>13</sup>C-NMR (CDCl<sub>3</sub>)  $\delta$ : 18.0 (C4'-Me), 32.9 (C5), 39.5 (C3), 40.4 (C6), 52.6 (C2), 64.6 (C4), 129.1 (C4'), 130.3 (C2'), 131.1 (C3'), 133.3 (C1'). IR (KBr): 3317 (OH), 2939, 2918, 1672, 1421, 1383 cm<sup>-1</sup>. MS  $m/z$  (%): 167 (M<sup>+</sup>, 100), 152 (77), 150 (41), 137 (27), 113 (100). HR-MS Calcd for C<sub>10</sub>H<sub>17</sub>NO: 167.1308. Found: 167.1303.

**Acknowledgments** This work was supported by a Grant-in-Aid for Scientific Research on the Priority Area of Reactive Organometallics (No. 05236101) from the Ministry of Education, Science and Culture, Japan.

#### References and Notes

- 1) Part III: Takemoto Y., Takeuchi J., Matsui E., Iwata C., *Chem. Pharm. Bull.*, **44**, 948—955 (1996).
- 2) Komoto T., Yano K., Ono J., Okawa J., Nakajima T., *Jpn. Kokai* 35788 ('86), Feb. 20, 1986, [*Chem. Abstr.*, **105**, 132137w (1986).]
- 3) a) Mayer M., Thiericke R., *J. Org. Chem.*, **58**, 3486—3489 (1993); b) Grabley S., Hammann P., Kluge H., Wink J., Kricke P., Zeeck A., *J. Antibiot.*, **44**, 797—800 (1991).
- 4) Howell J. A. S., Palin M. G., *Tetrahedron: Asymmetry*, **4**, 1241—1252 (1993); Franck-Neumann M., Martina D., Heitz M. P., *Tetrahedron Lett.*, **23**, 3493—3496 (1982).
- 5) a) Takemoto Y., Ueda S., Takeuchi J., Nakamoto T., Iwata C., Ohishi H., Sakaguchi K., Kusunoki M., *Chem., Pharm., Bull.*, **43**, 559—563 (1995); b) Takemoto Y., Ueda S., Takeuchi J., Nakamoto T., Iwata C., *Tetrahedron Lett.*, **35**, 8821—8824 (1994).
- 6) Franck-Neumann M., Briswalter C., Chemla P., Martina D., *Synlett*, **1990**, 637—640.
- 7) Nakanishi S., Kumeta K., Nakanishi J., Takata T., *Tetrahedron: Asymmetry*, **6**, 2097—2100 (1995).
- 8) Franck-Neumann M., Colson P.-J., *Synlett*, **1991**, 891-894; Fleet G. W. J., Harding P. J. C., *Tetrahedron Lett.*, **1979**, 975—978.
- 9) a) Greeves N., "Comprehensive Organic Synthesis," Vol. 8, ed. by Trost B. M., Fleming I., Pergamon Press, Oxford, 1991, pp. 1—24; b) Krishnamurthy S., Brown H. C., *J. Am. Chem. Soc.*, **98**, 3383—3384 (1976); c) Gemal A. L., Luche J. -L., *ibid.*, **103**, 5454—5459 (1981).
- 10) Kronenthal D. R., Han C. Y., Taylor N. K., *J. Org. Chem.*, **47**, 2765—2768 (1982); Mauldin C. H., Biehl E. R., Reeves P. C., *Tetrahedron Lett.*, **1972**, 2955—2958.